Scaffold hopping in de novo design. Ligand generation in the absence of receptor information

被引:61
作者
Lloyd, DG [1 ]
Buenemann, CL [1 ]
Todorov, NP [1 ]
Manallack, DT [1 ]
Dean, PM [1 ]
机构
[1] De Novo Pharmaceut, Cambridge CB4 9ZR, England
关键词
D O I
10.1021/jm034222u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report here the de novo generation of chemotypes and scaffolds for the estrogen receptor, without use of the receptor structure in the assembly phase. Through use of ligand superpositions or a single bound conformation of a known active, a pseudoreceptor can be generated as a design envelope, within which novel structures are readily assembled. Many of these structures have high similarity to known chemotypes. Scaffold hopping is readily achieved within this pseudoreceptor, indicating the advantages of such an approach in discovery research.
引用
收藏
页码:493 / 496
页数:4
相关论文
共 31 条
[1]   BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [J].
Babu, YS ;
Chand, P ;
Bantia, S ;
Kotian, P ;
Dehghani, A ;
El-Kattan, Y ;
Lin, TH ;
Hutchison, TL ;
Elliott, AJ ;
Parker, CD ;
Ananth, SL ;
Horn, LL ;
Laver, GW ;
Montgomery, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (19) :3482-3486
[2]  
Bogacewicz R, 2000, Acta Pol Pharm, V57 Suppl, P25
[3]   Molecular design based on 3D-pharmacophore.: Application to 5-HT4 receptor [J].
Bureau, R ;
Daveu, C ;
Lemaître, SP ;
Dauphin, F ;
Landelle, H ;
Lancelot, JC ;
Rault, S .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2002, 42 (04) :962-967
[4]   Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity [J].
Chand, P ;
Kotian, PL ;
Dehghani, A ;
El-Kattan, Y ;
Lin, TH ;
Hutchison, TL ;
Babu, YS ;
Bantia, S ;
Elliott, AJ ;
Montgomery, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4379-4392
[5]   Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE [J].
De Esch, IJP ;
Mills, JEJ ;
Perkins, TDJ ;
Romeo, G ;
Hoffmann, M ;
Wieland, K ;
Leurs, R ;
Menge, WMPB ;
Nederkoorn, PHJ ;
Dean, PM ;
Timmerman, H .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (11) :1666-1674
[6]   Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule [J].
DeLucca, GV ;
EricksonViitanen, S ;
Lam, PYS .
DRUG DISCOVERY TODAY, 1997, 2 (01) :6-18
[7]  
Guner Osman F., 2002, Current Topics in Medicinal Chemistry, V2, P1321, DOI 10.2174/1568026023392940
[8]  
HICKS S, 1999, CURR OPIN DRUG DISC, V2, P223
[9]   Recent developments in structure-based drug design [J].
Klebe, G .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2000, 78 (05) :269-281
[10]   The genesis of high-throughput structure-based drug discovery using protein crystallography [J].
Kuhn, P ;
Wilson, K ;
Patch, MG ;
Stevens, RC .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (05) :704-710